172 related articles for article (PubMed ID: 18294981)
1. Stroke prevention in atrial fibrillation: another step sideways.
Go AS; Singer DE
Lancet; 2008 Jan; 371(9609):278-80. PubMed ID: 18294981
[No Abstract] [Full Text] [Related]
2. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial.
; Bousser MG; Bouthier J; Büller HR; Cohen AT; Crijns H; Davidson BL; Halperin J; Hankey G; Levy S; Pengo V; Prandoni P; Prins MH; Tomkowski W; Torp-Pedersen C; Wyse DG
Lancet; 2008 Jan; 371(9609):315-21. PubMed ID: 18294998
[TBL] [Abstract][Full Text] [Related]
3. Terminated.
Rosendaal FR; Reitsma PH
J Thromb Haemost; 2014 Jun; 12(6):813. PubMed ID: 24916285
[No Abstract] [Full Text] [Related]
4. Clinical trials and tribulations.
Greaves M
J Thromb Haemost; 2014 Jun; 12(6):822-3. PubMed ID: 24655890
[No Abstract] [Full Text] [Related]
5. Pro: 'Warfarin should be the drug of choice for thromboprophylaxis in elderly patients with atrial fibrillation'. Why warfarin should really be the drug of choice for stroke prevention in elderly patients with atrial fibrillation.
Mant JW
Thromb Haemost; 2008 Jul; 100(1):14-5. PubMed ID: 18612531
[No Abstract] [Full Text] [Related]
6. Clinical practice. Care of patients receiving long-term anticoagulant therapy.
Schulman S
N Engl J Med; 2003 Aug; 349(7):675-83. PubMed ID: 12917305
[No Abstract] [Full Text] [Related]
7. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter.
Cairns JA; Connolly S; McMurtry S; Stephenson M; Talajic M;
Can J Cardiol; 2011; 27(1):74-90. PubMed ID: 21329865
[TBL] [Abstract][Full Text] [Related]
8. Will direct oral anticoagulants completely replace warfarin?
Thachil J
Br J Hosp Med (Lond); 2018 Nov; 79(11):604-605. PubMed ID: 30418820
[No Abstract] [Full Text] [Related]
9. Ximelagatran or warfarin for stroke prevention in patients with atrial fibrillation?
Hankey GJ; Klijn CJ; Eikelboom JW
Stroke; 2004 Feb; 35(2):389-91. PubMed ID: 14757889
[No Abstract] [Full Text] [Related]
10. Contra: 'Warfarin should be the drug of choice for thromboprophylaxis in elderly patients with atrial fibrillation'. Caveats regarding use of oral anticoagulant therapy among elderly patients with atrial fibrillation.
Hylek EM
Thromb Haemost; 2008 Jul; 100(1):16-7. PubMed ID: 18612532
[No Abstract] [Full Text] [Related]
11. Between the Devil and the Deep Blue Sea--balancing the risks and potential benefits of warfarin for older people with atrial fibrillation.
Morgan SV
Age Ageing; 2004 Nov; 33(6):544-7. PubMed ID: 15501835
[No Abstract] [Full Text] [Related]
12. Bleeding rates in elderly patients on vitamin K antagonist therapy for nonvalvular atrial fibrillation.
Tay KH; Lip GY; Lane DA
Blood Coagul Fibrinolysis; 2009 Jul; 20(5):392-3. PubMed ID: 19542940
[No Abstract] [Full Text] [Related]
13. [Atrial fibrillation: new anticoagulants are more effective and safer, but expensive].
Steurer J
Praxis (Bern 1994); 2014 Jun; 103(13):785-6. PubMed ID: 24938162
[No Abstract] [Full Text] [Related]
14. Ximelagatran or warfarin in atrial fibrillation?
Stöllberger C; Finsterer J
Lancet; 2004 Feb; 363(9410):734-5; author reply 736. PubMed ID: 15001336
[No Abstract] [Full Text] [Related]
15. Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.
Chevalier J; Delaitre O; Hammès F; de Pouvourville G
Arch Cardiovasc Dis; 2014; 107(6-7):381-90. PubMed ID: 24973113
[TBL] [Abstract][Full Text] [Related]
16. [Oral anticoagulants. Large study finds minor risk of hemorrhage in the elderly].
MMW Fortschr Med; 2011 Sep; 153(37):16. PubMed ID: 21950182
[No Abstract] [Full Text] [Related]
17. Summaries for patients. Rivaroxaban in patients transitioned from vitamin K antagonist therapy.
Ann Intern Med; 2013 Jun; 158(12):I-28. PubMed ID: 23778921
[No Abstract] [Full Text] [Related]
18. New therapies for stroke prevention in atrial fibrillation: the long road to enhanced efficacy.
Freedman JE; Gersh BJ
Circulation; 2009 Sep; 120(12):1024-6. PubMed ID: 19738132
[No Abstract] [Full Text] [Related]
19. Do A-fib patients continue to benefit from vitamin K antagonists with advancing age?
Guthmann R; Bahrami A; Martin R; Nashelsky J
J Fam Pract; 2019; 68(6):E12-E14. PubMed ID: 31381630
[No Abstract] [Full Text] [Related]
20. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study.
ROCKET AF Study Investigators
Am Heart J; 2010 Mar; 159(3):340-347.e1. PubMed ID: 20211293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
